Patents Assigned to Promega Corporation
  • Patent number: 11691976
    Abstract: Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: July 4, 2023
    Assignee: Promega Corporation
    Inventors: Joel R. Walker, Thomas A. Kirkland, Wenhui Zhou, Mary P. Hall, Harry Tetsuo Uyeda
  • Patent number: 11692983
    Abstract: The present invention provides reagents for instrumentation quality control and methods of use thereof. In particular, sets of peptides or other molecules are provided for evaluating the performance of instruments with mass spectrometry (MS) and/or liquid chromatography (LC) functionalities.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: July 4, 2023
    Assignee: Promega Corporation
    Inventors: Joshua Jacques Coon, Michael M. Rosenblatt, Marjeta Urh
  • Patent number: 11667950
    Abstract: A polynucleotide encoding a modified luciferase polypeptide. The modified luciferase polypeptide has at least 60% amino acid sequence identity to a wild-type Oplophorus luciferase and includes at least one amino acid substitution at a position corresponding to an amino acid in a wild-type Oplophorus luciferase of SEQ ID NO: 1. The modified luciferase polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the wild-type Oplophorus luciferase.
    Type: Grant
    Filed: June 20, 2022
    Date of Patent: June 6, 2023
    Assignee: Promega Corporation
    Inventors: Lance P. Encell, Mary Hall, Paul Otto, Gediminas Vidugiris, Keith V. Wood, Monika G. Wood, Kristopher Zimmerman
  • Patent number: 11667648
    Abstract: Provided herein are cell-permeable, cell-compatible, and chemoselectively-cleavable linkers for tethering (e.g., covalently) functional elements (e.g., a cellular interaction element and a capture element), and methods of use (e.g., intracellular capture and extracellular release of cellular targets) therewith.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: June 6, 2023
    Assignee: Promega Corporation
    Inventors: Sergiy Levin, Rachel Friedman Ohana, Thomas Kirkland, Keith V. Wood
  • Patent number: 11661623
    Abstract: An isolated polynucleotide encoding a modified luciferase polypeptide and substrates. The OgLuc variant polypeptide has at least 60% amino acid sequence identity to SEQ ID NO: 1 and at least one amino acid substitution at a position corresponding to an amino acid in SEQ ID NO: 1. The OgLuc variant polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the corresponding polypeptide of the wild-type Oplophorus luciferase.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: May 30, 2023
    Assignee: PROMEGA CORPORATION
    Inventors: Brock Binkowski, Lance P. Encell, Mary Hall, Matthew B. Robers, Michael R. Slater, Keith V. Wood, Monika G. Wood, Dieter Klaubert, Poncho Meisenheimer, James Unch, Michael P. Valley
  • Patent number: 11661587
    Abstract: Disclosed are luciferase polypeptides with improved light-emitting activity and their encoding nucleic acids. These molecules are useful in a range of assays including luciferase-based gene reporter assays, bioluminescence resonance energy transfer assays, protein complementation assays and other applications in which luciferase enzymes are utilized as detectable and/or quantifiable labels. Also disclosed are methods and compositions for increasing the sensitivity and/or improving the kinetics of luciferase-catalyzed reactions as well as decreasing the impact of undesirable variables.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: May 30, 2023
    Assignee: Promega Corporation
    Inventors: John Michael Daly, Leon Michael Brownrigg, Jim Yu-Hsiang Tiao
  • Patent number: 11655247
    Abstract: Compounds that may inhibit Oplophorus-derived luciferases are disclosed as well as compositions and kits comprising the compounds and methods of using the compounds.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: May 23, 2023
    Assignee: Promega Corporation
    Inventors: Brock Binkowski, Mary P. Hall, Thomas Machleidt, Joel Walker, Wenhui Zhou
  • Patent number: 11624041
    Abstract: The invention provides surfactant compounds of formulas I-IX, which can be used in methods for aiding the solubilization, digestion, preparation, analysis, and/or characterization of biological material, for example, proteins or cell membranes. The compounds can also aid in the recovery of peptides generated during protein digestion, particularly for in-gel digestion protocol. Additionally, the compounds can improve enzymatic protein deglycosylation without interfering with downstream sample preparation steps and mass spectrometric analysis. The compounds can be specifically useful as digestion aids that can be decomposed by an acid, by heat, or a combination thereof. Decomposition of the surfactants allows for facile separation from isolated samples, and/or allows for analysis of the sample without interfering with the sensitivity of various analytical techniques.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: April 11, 2023
    Assignee: Promega Corporation
    Inventors: Sergei Saveliev, Daniel Simpson, Keith V. Wood, Harry Tetsuo Uyeda, Carolyn Woodroofe Hitko, Dieter Klaubert
  • Patent number: 11567083
    Abstract: Provided herein are systems and methods for characterizing target/ligand engagement. In particular, luciferase-labeled polypeptide targets are used to detect or quantify target/ligand engagement (e.g., within a cell or cell lysate).
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: January 31, 2023
    Assignee: Promega Corporation
    Inventors: Melanie Dart, Lance P. Encell, Thomas Kirkland, Thomas Machleidt, Matthew Robers, Brock F. Binkowski, Keith Wood, Ce Shi
  • Patent number: 11534504
    Abstract: Provided herein are compositions and methods for stabilizing coelenterazine and analogs or derivatives thereof, and for improving the solubility and reconstitution efficiency of coelenterazine and analogs and derivatives thereof.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: December 27, 2022
    Assignee: Promega Corporation
    Inventors: Melanie Dart, Thomas Smith, Thomas Kirkland, Thomas Machleidt, Keith Wood
  • Patent number: 11524946
    Abstract: The present disclosure includes compositions and methods for improved DNA amplification reactions. In particular, the present disclosure provides compositions and methods for hot-start PCR applications using DNA polymerase inhibitors that minimize non-specific DNA amplification by inactivating DNA polymerase at lower temperatures.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: December 13, 2022
    Assignee: Promega Corporation
    Inventors: Wenhui Zhou, Kimberly K. Knoche, Douglas R. Storts, Min Zhou, Poncho Meisenheimer
  • Patent number: 11493504
    Abstract: Provided herein are compositions and methods for the assembly of a bioluminescent complex from two or more non-luminescent (e.g., substantially non-luminescent) peptide and/or polypeptide units. In particular, bioluminescent activity is conferred upon a non-luminescent polypeptide via structural complementation with another, complementary non-luminescent peptide.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: November 8, 2022
    Assignee: Promega Corporation
    Inventors: Andrew S. Dixon, Lance Encell, Mary Hall, Keith Wood, Monika Wood, Marie Schwinn, Brock F. Binkowski, Hicham Zegzouti, Nidhi Nath, Subhanjan Mondal, Said Goueli, Poncho Meisenheimer, Thomas Kirkland, James Unch, Dileep K. Pulukkunat, Matthew Robers, Melanie Dart, Thomas Machleidt
  • Patent number: 11442063
    Abstract: Provided herein are compounds that are broad-spectrum protein kinase binding agents, detectable tracers comprising such compounds, and method of use thereof for the detection of protein kinases.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: September 13, 2022
    Assignee: Promega Corporation
    Inventors: Cesear Corona, Poncho Meisenheimer, Matthew Robers, James Vasta
  • Patent number: 11390599
    Abstract: Compounds that may selectively inhibit Oplophorus luciferase-derived bioluminescent complexes, e.g., NanoBiT® bioluminescent complex, are disclosed as well as compositions and kits comprising the compounds, and methods of using the compounds.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: July 19, 2022
    Assignee: Promega Corporation
    Inventors: Joel R. Walker, Mary Hall, Christopher Todd Eggers, Horacio Lazaro
  • Patent number: 11365436
    Abstract: A polynucleotide encoding a modified luciferase polypeptide. The modified luciferase polypeptide has at least 60% amino acid sequence identity to a wild-type Oplophorus luciferase and includes at least one amino acid substitution at a position corresponding to an amino acid in a wild-type Oplophorus luciferase of SEQ ID NO:1. The modified luciferase polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the wild-type Oplophorus luciferase.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: June 21, 2022
    Assignee: Promega Corporation
    Inventors: Lance P. Encell, Mary Hall, Paul Otto, Gediminas Vidugiris, Keith V. Wood, Monika G. Wood, Kristopher Zimmerman
  • Patent number: 11365402
    Abstract: Provided herein are substantially non-luminescent peptide/polypeptide tags that are inserted internally within a protein of interest or between N-terminal and C-terminal peptides/polypeptides. Interaction of the internally-inserted tag with a complement polypeptide/peptide that is also substantially non-luminescent results in the formation a bioluminescent reporter complex.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: June 21, 2022
    Assignee: Promega Corporation
    Inventors: Andrew S. Dixon, Lance P. Encell, Thomas Machleidt, Marie Schwinn, Keith Wood, Monika Wood, Kris Zimmerman
  • Patent number: 11293047
    Abstract: Provided herein are isolated polynucleotide encoding modified click beetle luciferase polypeptides that have enhanced luminescence and longer wavelength near-infrared signals. The disclosure also relates to near-infrared bioluminescence systems that include said modified click beetle luciferase polypeptides and novel luciferin derivatives, as well as methods of using said modified click beetle luciferase polypeptides and bioluminescence systems.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: April 5, 2022
    Assignee: Promega Corporation
    Inventors: Lance P. Encell, Mary P. Hall, Keith V. Wood, Monika G. Wood
  • Publication number: 20220064696
    Abstract: Provided herein are systems, methods, and compounds for identifying RAS binding compounds using a RAS binding agent, which comprises a RAS binding moiety and a functional element. In some embodiments, the RAS binding agent binds to one site on the RAS protein (e.g., KRAS, HRAS, or NRAS), and can be used to detect RAS binding agents that bind to the same site as well as other sites.
    Type: Application
    Filed: August 27, 2021
    Publication date: March 3, 2022
    Applicant: Promega Corporation
    Inventors: Matthew B. Robers, Joel R. Walker, James Vasta, Cesear Corona
  • Patent number: 11261478
    Abstract: Provided herein are inhibitor-resistant luciferase mutants, and methods of use thereof. In particular, luciferase mutants are provided that are thermal stable and exhibit improved stability in the presence of luciferin break-down products, such as dehydroluciferin. Further provided are assay systems comprising inhibitor-resistant luciferase mutants and amino acid sequences of the inhibitor-resistant luciferase mutants.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: March 1, 2022
    Assignee: Promega Corporation
    Inventors: Ce Shi, Thomas Kirkland, Poncho Meisenheimer, Lance P. Encell, Mary Hall
  • Patent number: 11214822
    Abstract: Methods, kits and compositions containing a mixture of D-luciferin and L-luciferin for light generation with luciferase are disclosed that have improved stability when stored over time. The mixture of D-luciferin and L-luciferin can be used to detect the presence or amount of ATP or of luciferase in a sample.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: January 4, 2022
    Assignee: PROMEGA CORPORATION
    Inventors: Michael P. Valley, James J. Cali, Brock Binkowski, Christopher Todd Eggers, Keith V. Wood